Disappointment in the Market as Hopes for a "Global Big Deal" Fade
Exclusive Semaglutide Contract Limits Further Technology Transfer Opportunities
"Platform Deal Value Undervalued... Combination Therapies May Be a Game Changer"

The share price of G2GBIO, which recently announced a technology collaboration agreement with Samsung Bioepis, has been declining for several consecutive days. The market sentiment suggests that this contract falls short of expectations that had built up around the possibility of a global big deal.


According to the bio and investment industries on March 19, G2GBIO closed at 91,600 won on the KOSDAQ market the previous day, down 2.03% compared to March 17. Since the simultaneous announcement on March 16 of a convertible bond (CB) investment from Samsung Episholdings and a three-party contract with Samsung Bioepis and Epis Nexlab, the stock has been on a downward trend for three consecutive trading sessions. Compared to the closing price of 118,800 won on March 13, this represents a sharp drop of about 23%.

Even Samsung-Driven Good News Fails to Lift G2GBIO... What Is Happening? View original image

This contract is a joint development and licensing agreement for a long-acting formulation based on semaglutide, an ingredient used in obesity treatments. Samsung Bioepis secured exclusive development rights to two candidate substances, including this ingredient. Separately, Samsung Episholdings signed a convertible bond investment agreement worth 20 billion won.


However, as expectations for technology transfer based on semaglutide have diminished due to this contract, the core premium that had been supporting G2GBIO’s share price has also decreased. Market analysts point out that, given the ongoing speculation about the possibility of a major technology transfer deal with a global big pharma company, the disappointment in the market has been even greater. G2GBIO previously entered into a joint development agreement with global big pharma company A in 2023 for semaglutide, and last year signed two contracts with Boehringer Ingelheim. In September of the same year, it also signed a joint development agreement with a global pharmaceutical company based in Europe.


It is reported that the failure to finalize the technology transfer agreement with company A stemmed from disagreements over exclusive rights for the drug class. Company A demanded class exclusivity for semaglutide, delaying negotiations. Accepting this would have restricted G2GBIO from making deals with other companies not only for monotherapy but also for combination therapies. Considering that patents for semaglutide are set to expire in Europe in 2031 and in the United States in 2032, it appears that G2GBIO determined it could not afford further delays in development timelines.


Jung Youkyoung, a researcher at Shin Young Securities, commented, "Although negotiations for a technology deal on semaglutide monotherapy with global company A have been halted, discussions on combination therapies such as amylin combination drug Cagrisema, as well as on other APIs, are ongoing as before. The market had formed a consensus around a possible contract with global company A, so the newly announced deal, which was seen as less favorable, has resulted in an excessive level of disappointment."



Lee Heeyong, CEO of G2GBIO, stated, "The ongoing discussions for technology transfer with the big pharma companies we previously signed joint development agreements with are unrelated to this exclusive technology transfer agreement for semaglutide." He added, "Although there is an aspect where the company's value has not been properly recognized due to market misunderstandings, we will prove our worth through future achievements."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing